References
- El-Harazi SM, Feldman RM. Control of intra-ocular inflammation associated with cataract surgery. Curr Opin Ophthalmol. 2001;12:4–8.
- Mohammadpour M, Jafarinasab MR, Javadi MA. Outcomes of acute postoperative inflammation after cataract surgery. Eur J Ophthalmol. 2007;17:20–28.
- Campos, M., Ávila, M, Wallau, A, et al. Efficacy and tolerability of a fixed-dose moxifloxacin – dexamethasone formulation for topical prophylaxis in LASIK: A comparative, double-masked clinical trial. Clin Ophthalmol. 2008;2:331–338.
- Holland EJ, Djalilian AR, Sanderson JP. Attenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantation. Cornea. 2009;28:1139–1143.
- Seah SK, Husain R, Gazzard G, et al. Use of surodex in phacotrabeculectomy surgery. Am J Ophthalmol. 2005;139:927–928.
- Loteprednol Etabonate US Uveitis Study Group. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Am J Ophthalmol. 1999;127:537–544.
- Grigorian RA, Shah A, Guo S. Comparison of loteprednol etabonate 0.5% (Lotemax) to prednisolone acetate 1% (Falcon) for inflammation treatment following cataract surgery. Invest Ophthalmol Vis Sci. 2007;48:1065.
- Kaur R, Matreja PS, Khan B, Bhatnagar RN. Compare the safety and efficacy of loteprendol etabonate 0.5% and prednisolone acetate 1% in the post operative inflammation following cataract extraction with intra ocular lens (IOL) implant. Ann Appl Bio-Sci. 2015;2: 106–110.
- Lane SS, Holland EJ. Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery. J Cataract Refract Surg. 2013;39:168–173.
- Frangie JP, Leibowitz HM. Steroids. Int Ophthalmol Clin. 1993;33:9–29.
- Bielory L. Ocular allergy treatment. Immunol Allergy Clin North Am. 2008;28:189–224, vii.
- A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. The Loteprednol Etabonate Postoperative Inflammation Study Group 2. Ophthalmol. 1998;105:1780–1786.
- Assil KK, Massry G, Lehmann R, Fox K, Stewart R. Control of ocular inflammation after cataract extraction with rimexolone 1% ophthalmic suspension. J Cataract Refract Surg. 1997;23:750–757.
- Korenfeld MS, Silverstein SM, Cooke DL, Vogel R, Crockett RS. Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain. J Cataract Refract Surg. 2009;35:26–34.
- Druzgala P, Hochhaus G, Bodor N. Soft drugs–10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate. J Steroid Biochem Mol Biol. 1991;38:149–154.
- Pirouzian A, Craven ER. Critical appraisal of loteprednol ointment, gel, and suspension in the treatment of postoperative inflammation and pain following ocular and corneal transplant surgery. Clin Ophthalmol. 2014;8:379–387.
- Albert M, Wu. W, Winwood D, Bodor N. Lipophilicity, solubility and permeability of loteprednol etabonate: a novel, soft anti-inflammatory steroid. J Biopharm Sci. 1991;2:115–125.
- Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509–516.
- Scott J, Huskisson EC. Vertical or horizontal visual analogue scales. Ann Rheum Dis. 1979;38:560.
- Amon M, Busin M. Loteprednol etabonate ophthalmic suspension 0.5%: efficacy and safety for postoperative anti-inflammatory use. Int Ophthalmol. 2012;32:507–517.
- Wilson ME, O’Halloran H, VanderVeen D, et al. Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: a randomized safety and efficacy study. Eye (Lond). 2016;30:1187–1194.
- Sheppard JD, Comstock TL, Cavet ME. Impact of the topical ophthalmic corticosteroid loteprednol etabonate on intraocular pressure. Adv Ther. 2016;33:532–552.
- Yu JG, Ni F, Xiang, Y., et al. A prospective study on postoperative discomfort after 20-gauge pars plana vitrectomy. Clin Ophthalmol. 2015;9:1379–1384.
- Comstock TL, Usner DL, Effect of Loteprednol Etabonate Ophthalmic Suspension 0.5% on Post-Operative Pain and Discomfort. Poster presented at the American Society of Cataract and Refractive Surgery Annual Symposium, Boston, Massachusetts, USA, April 9–14, 2010.
- Jonas JB, Knorr HL, Rank RM, Budde WM. Intraocular pressure and silicone oil endotamponade. J Glaucoma. 2001;10:102–108.
- Chang S, Lincoff HA, Coleman DJ, Fuchs W, Farber ME. Perfluorocarbon gases in vitreous surgery. Ophthalmol. 1985;92:651–656.